News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major news articles were published in the past hour.
  • Global equity and bond markets had no new catalysts reported in the last hour.
  • No fresh central bank announcements or policy moves occurred in the past hour.
  • No significant corporate earnings or M&A headlines emerged in the last hour.
  • No major geopolitical developments or conflicts were reported during the past hour.
  • Economic indicators and market-moving data releases were absent in the past hour.

Latest Articles

Oxford Lane Capital Corp. Provides August 2026 Net Asset Value Update

Oxford Lane Capital Corp. Provides August 2026 Net Asset Value Update

Oxford Lane Capital Corp. announced an unaudited estimate of its net asset value (NAV) per share for August 31, 2026, between $10.34 and $10.64. The company cautioned this estimate is preliminary, not approved by the board, and may materially differ from the September quarter-end NAV. The firm is a closed-end management investment company focused o…

FactSet to Host Investor Day on November 10, 2026

FactSet to Host Investor Day on November 10, 2026

FactSet Research Systems Inc. has scheduled its Investor Day on November 10, 2026, in New York City and via webcast. The event will feature presentations from the CEO, CFO, and executive leadership about the company’s strategy, product roadmap, and financial outlook, including demonstrations of AI-driven solutions. Presentation materials will be av…

Evaxion applies its AI-Immunology™ platform in autoimmune diseases

Evaxion applies its AI-Immunology™ platform in autoimmune diseases

Evaxion A/S has initiated experimental application of its AI-Immunology™ platform in autoimmune diseases by testing two novel treatment concepts – a tolerogenic vaccine and an autoantibody binder. These approaches aim to target underlying disease pathologies with high specificity, potentially leading to more effective and safer therapies than curre…

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Akebia Therapeutics has dosed the first patient in its open-label Phase 2 basket trial of ebribafusp, an investigational anti-C3d factor H fusion protein designed to inhibit complement activation in kidney tissue without suppressing the blood complement system. The trial targets rare kidney diseases including IgA nephropathy, lupus nephritis, and C…

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

Radiopharm Theranostics revealed encouraging interim results from its Phase 2b trial of RAD101, a PET imaging agent targeting fatty acid synthase in suspected recurrent brain metastases. The 93% concordance with MRI and preliminary 86% sensitivity highlight RAD101's potential to improve diagnostic accuracy where current imaging methods are limited.…

Linkage Global Signs Non-Binding Letter of Intent for Strategic PIPE Investment of Up to $20 Million from Capital Finance Limited

Linkage Global Signs Non-Binding Letter of Intent for Strategic PIPE Investment of Up to $20 Million from Capital Finance Limited

Linkage Global Inc., a US-listed company focused on AI-driven wellness solutions, has signed a non-binding letter of intent with Capital Finance Limited for up to $20 million in a two-tranche PIPE investment. The investment aims to accelerate development of AI-enabled wellness infrastructure and fund a strategic acquisition of an AI hardware manufa…

Live Oak Bank Named Official Business Bank of UNCW Athletics

Live Oak Bank Named Official Business Bank of UNCW Athletics

Live Oak Bank, a subsidiary of Live Oak Bancshares, Inc. (NYSE: LOB), has been named the Official Business Bank of UNCW Athletics under a multi-year agreement. This partnership enhances Live Oak's community presence, particularly in Wilmington, NC, and strengthens its connection with local small businesses and university alumni. The bank continues …

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis

Nasus Pharma received FDA clearance to start clinical studies for NS002, an investigational intranasal epinephrine powder intended as a needle-free alternative to EpiPen for treating anaphylaxis. The pivotal study is planned for Q4 2026, with topline data expected in Q1 2027, aiming to address a $2 billion market by offering faster and more patient…

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

Telomir Pharmaceuticals announced new research from The Ohio State University demonstrating that their compound Telomir-Zn inhibits cell growth effectively in human and canine osteosarcoma cell lines, suggesting potential for both veterinary and human therapeutic development. The company is advancing its triple-negative breast cancer (TNBC) program…

Aqua Metals Signs Five-Year Copper and Aluminum Offtake LOI, Completing Commercial Coverage of Three Project Headwaters Product Streams

Aqua Metals Signs Five-Year Copper and Aluminum Offtake LOI, Completing Commercial Coverage of Three Project Headwaters Product Streams

Aqua Metals announced a non-binding five-year letter of intent with a leading Midwest metals recycler to offtake up to 100% of the copper and aluminum recovered from its Project Headwaters lithium-ion battery recycling facility. This agreement complements a previously announced lithium carbonate offtake, establishing commercial pathways for all mai…

Upexi Amends BitGo Credit Facility

Upexi Amends BitGo Credit Facility

Upexi, Inc. amended its credit facility with BitGo Prime, lowering the interest rate from 11.5% to 7.5% and reducing collateral requirements. This is expected to save over $2 million annually in interest costs and provide greater financial flexibility, supporting its strategy to accumulate Solana tokens and enhance shareholder value.

Satellogic Supports HEO RPO Mission Operations

Satellogic Supports HEO RPO Mission Operations

Satellogic's Continuum-1 Earth observation satellite, recently acquired by HEO, successfully completed two extended proximity operation phases involving close inspection of a derelict Chinese rocket body in low-Earth orbit. This demonstration highlights the satellite's software capabilities beyond its original design, paving the way for sovereign s…

CoinShares Announces First Half 2026 Results

CoinShares Announces First Half 2026 Results

CoinShares PLC released its H1 2026 financial results showing total revenue declined to $51.4 million from $80 million the prior year, driven by lower digital asset prices impacting assets under management (AUM), which fell to $5.5 billion from $7.4 billion at end-2025. Despite this, the company generated $27.6 million in net inflows, reflecting cl…

MPC: Ride the Refining Cycle - A $402 Entry for a 180‑Day Upside Trade

MPC: Ride the Refining Cycle - A $402 Entry for a 180‑Day Upside Trade

Marathon Petroleum (MPC) looks positioned to capture continued upside as tight refined‑product markets and elevated crack spreads sustain unusually strong refining profits. The company’s Q2 outperformance, large free cash flow generation and capital returns give a favorable risk/reward for a disciplined long trade sized to a 180 trading‑day horizon…

Buy the Turnaround: Norwegian Cruise Line at a Sub-9x Earnings Multiple

Buy the Turnaround: Norwegian Cruise Line at a Sub-9x Earnings Multiple

Norwegian Cruise Line (NCLH) trades below $15 and beneath pre-2026 highs despite a clear path to margin recovery if management executes on pricing and operations. At roughly 9x reported earnings and an EV/EBITDA under 8x, the market is pricing in a deep downside scenario. This trade targets a mid-term recovery tied to booking momentum, yield stabil…